Ireland
--:--IST
Clinical Trials in the EU / 2025-524810-28-00
Authorised, recruiting Phase III

A Pivotal Open-label Phase 3 Clinical Study Evaluating the Efficacy and Safety of QTX-2101 in Combination With All-trans Retinoic Acid in Newly Diagnosed, Low-risk Acute Promyelocytic Leukemia

2025-524810-28-00 · tracked via the Priya Life Science EU tracker
Sponsor
Quetzal Therapeutics LLC
Sponsor type
Pharmaceutical company
Therapeutic area
Neoplasms
Decision date
13/05/2026
Enrollment target
89
Sites
Germany, Poland, Spain, Romania, Italy, France

Condition studied

Acute Promyelocytic Leukemia

Investigational medicinal product(s)

QTX-2101Arsenic trioxide Accord 1 mg/ml concentrate for solution for infusion

Every trial of Arsenic Trioxide across our registers →

Eligibility

Age group
65+ years, 18-64 years
Sex
Female, Male

Primary endpoint

PK parameters, including maximum plasma concentration (Cmax) and area under curve (AUC) for all metabolites of arsenic trioxide, including arsenious acid (AsIII), arsenic acid (ASV), total arsenic, dimethylarsinic acid (DMA), and monomethylarsenic acid (MMA)., Molecular complete remission (mCR) defined as absence of promyelocytic leukemia/ retinoic acid receptor alpha (PML/RARA) in the bone marrow per European Leukemia Net (ELN) 2019 criteria for APL. Negativity of PML/RARA is defined as PML/RARA transcript level below 10-4, confirmed by centralized quantitative reverse transcription-polymerase chain reaction (RTqPCR) testing using an assay with a limit of detection (LOD) of 10-5.

Endpoint detail

Incidence of adverse events (AEs), clinically significant laboratory changes, significant electrocardiogram (ECG) findings, and vital sign changes., Landmark EFS at the time of the primary endpoint analysis, defined as time from randomization to the date of induction treatment failure (failure to achieve complete remission [CR]/morphologic complete remission [CRi] after induction), no achievement of mCR after 3 consolidation courses, relapse after CR/mCR, or death from any cause, whichever comes first., Other parameters of efficacy, including CR/CRi rate, defined as achieving CR/CRi at the end of induction and end of Consolidation Cycle 3 per ELN 2019 criteria for APL and landmark overall survival (OS), defined as duration from randomization to date of death due to any cause, Incidences of AEs, clinically significant laboratory changes, significant ECG, and vital sign changes, Summary statistics of QTX-2101 steady-state AUC and Cmax, determined by population PK analysis., Triplicate ECGs with time-matched PK sampling analysis., Participant-reported outcomes assessing quality of life (eg, EORTC QLQ-C30), treatment convenience and satisfaction (eg, CCSQ), health utility (eg, EQ-5D-5L), and overall treatment burden (eg, number of infusion visits, catheter use, and time in treatment)

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-524810-28-00 on CTIS ↗ ← All trials in the EU